Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025Molecular OncologyOpen Access

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

View Full Paper
Ask AI
Bookmark
Share

Authors

SWShuangshuang WuJZJianlei ZhaoAAAsfar S. Azmi

Discussion

Loading...

Member takes

Overview

Combination therapy of CDK9 inhibitor AZD4573 enhances AML cell death with venetoclax and azacitidine, indicating potential for improved treatment.

Key Points

  • AZD4573 significantly increases AML cell death when combined with venetoclax and azacitidine.
  • Elevated mTORC1 signaling in AraC-resistant AML cells underscores the need for new treatment strategies.
  • The combination therapy spares normal hematopoietic progenitor cells while targeting AML progenitor cells.
  • This approach shows efficacy even with reduced concentrations of venetoclax, suggesting flexibility in dosing.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/68d42f56713b0b5dfea704e3https://doi.org/10.1002/1878-0261.70124
View Full Paper
Ask AI
Bookmark
Share